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Normal Glucose-Induced Suppression of Glucose
Production But Impaired Stimulation of Glucose
Disposal in Type 2 Diabetes
Evidence for a Concentration-Dependent Defect in Uptake
Michael F. Nielsen, Rita Basu, Steven Wise, Andrea Caumo, Claudio Cobelli, and Robert A. Rizza
The present studies were undertaken to determine
whether people with type 2 diabetes are resistant to
the effects of glucose as well as insulin. Diabetic and
nondiabetic subjects were studied on three occasions.
Hormone secretion was inhibited with somatostatin.
Insulin concentrations were kept at “basal” levels
(referred to as low insulin infusion) from 0 to 180 min
then increased to ~200 pmol/l from 181 to 360 min
(referred to as high insulin infusion). Glucose concen-
trations were clamped at either ~95, ~130, or ~165
mg/dl on each occasion. In the presence of basal insulin
concentrations, a progressive increase in glucose from
95 to 130 to 165 mg/dl was accompanied by a compara-
ble and progressive decrease (P = 0.001 to 0.003 by
analysis of variance [ANOVA]) in endogenous glucose
production (measured with [6-3H]glucose) and total glu-
cose output (measured with [2-3H]glucose) and incor-
poration of 1 4C O2 into glucose (an index of gluconeoge-
nesis) in both diabetic and nondiabetic subjects, indi-
cating normal hepatic (and perhaps renal) response to
glucose. In the nondiabetic subjects, an increase in glu-
cose concentration from 95 to 130 to 165 mg/dl resulted
in a progressive increase in glucose disappearance dur-
ing both the low (19.9 ± 1.8 to 23.6 ± 1.8 to 25.4 ± 1.6
µmol · kg– 1 · min– 1; P = 0.003 by ANOVA) and high (36.4
± 3.1 to 47.6 ± 4.5 to 61.1 ± 7.0 µmol · kg– 1 · min– 1; P =
0.001 by ANOVA) insulin infusions. In contrast, in the
diabetic subjects, whereas an increase in glucose from
95 to 130 mg/dl resulted in an increase in glucose dis-
appearance during both the low (P = 0.001) and high (P
= 0.01) dose insulin infusions, a further increase in glu-
cose concentration to 165 mg/dl had no further effect (P
= 0.41 and 0.38) on disappearance at either insulin dose
(low: 14.2 ± 0.8 to 18.2 ± 1.1 to 18.7 ± 2.4 µmol · kg– 1 ·
m i n– 1; high: 21.0 ± 3.2 to 33.9 ± 6.4 to 32.5 ± 8.0 µmol ·
k g– 1 · min– 1 for 95, 130, and 165 mg/dl, respectively). We
conclude that whereas glucose-induced stimulation of its
own uptake is abnormal in type 2 diabetes, glucose-
induced suppression of endogenous glucose production
and output is not. The abnormality in uptake occurs in
the presence of both basal and high insulin concentra-
tions and is evident at glucose concentrations above
but not below 130 mg/dl, implying a defect in a glucose-
responsive step. D i a b e t e s 47:1735–1747, 1998
People with poorly controlled type 2 diabetes haveinappropriately high rates of glucose productionand inappropriately low rates of glucose disposal(1–3). Both are regulated by the prevailing insulin
and glucose concentrations (4–9). While there is general
agreement that type 2 diabetes is associated with insulin
resistance (9–12), it is less clear whether glucose effectiveness
( d e fined as the ability of glucose to stimulate its own uptake
and to suppress its own release) is also impaired. In the past,
many investigators have used the so-called minimal model
(13) to assess glucose effectiveness in diabetic patients
(14–18). These experiments, in general, have reported that SG
( d e fined as glucose effectiveness in the presence of basal
insulin concentrations) is decreased in type 2 diabetes
(14–16,18). However, it has recently become evident that
while the minimal model yields a useful estimate of insulin
action (referred to as the insulin sensitivity index or SI), its
ability to accurately assess glucose effectiveness is open to
question (19–21). In addition, the minimal model merely
measures net glucose effectiveness and net insulin action. It
therefore cannot determine whether changes in SG or SI a r e
due to alterations in glucose production, glucose utilization,
or a combination of both.
Several alternative approaches have been used in an effort
to circumvent these limitations. We initially attempted to
measure insulin action and glucose effectiveness during
insulin infusions that mimicked postprandial peripheral
insulin concentrations (22). Glucose concentrations were
clamped at euglycemic levels or varied so as to reproduce a
pattern resembling that normally observed in nondiabetic
individuals after food ingestion. Results obtained during the
euglycemic experiments were used as a measure of insulin
action. Glucose effectiveness was calculated by subtracting
the rates of glucose production and utilization observed dur-
ing the euglycemic experiments from those observed during
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the hyperglycemic experiments. Insulin action measured in
this manner was impaired in the diabetic subjects, while glu-
cose effectiveness was normal (22). However, those experi-
ments examined glucose effectiveness in the presence of
high insulin concentrations, whereas the previous experi-
ments using the minimal model examined glucose effective-
ness in the presence of basal insulin concentrations. We
therefore performed additional experiments in which glu-
cose effectiveness was assessed by measuring the glycemic
excursion observed when fixed amounts of labeled and unla-
beled glucose were infused in the presence of individually
determined basal insulin concentrations (23). Those experi-
ments indicated that the ability of glucose to stimulate its own
uptake in the presence of basal insulin concentrations was
impaired in type 2 diabetes (23). This conclusion was con-
firmed in other studies using either the glucose clamp tech-
nique (24) or the so-called hot minimal model in which tracer
and cold glucose are injected concurrently (25).
We were puzzled by the above findings because they
seemed to imply that, despite the presence of insulin resis-
tance, high insulin levels somehow reversed a defect in the
ability of glucose to stimulate its own uptake. Alternatively,
the apparent differences between studies could have been due
to differences in methods used to assess glucose effective-
ness, differences in subject characteristics, or chance alone.
In addition, our earlier studies were not conclusive as to
whether the hepatic response to glucose was also abnormal.
Glucose infusion in the presence of basal insulin concentra-
tions suppressed glucose production in both diabetic and
nondiabetic subjects. However, glucose concentrations dif-
fered between groups and production did not return to basal
in those studies, making it difficult to determine whether the
degree of suppression was truly appropriate in the diabetic
subjects (23).
The present studies, therefore, were undertaken to
address these questions. Specific a l l y, we sought to test the
hypotheses that glucose-induced suppression of production
and glucose-induced stimulation of uptake are impaired in
type 2 diabetes. We further hypothesized that the defect in glu-
cose-induced stimulation of uptake would be evident at low
but not high insulin concentrations. We report that both of
these hypotheses are incorrect. Although glucose-induced
stimulation of uptake is impaired in people with type 2 dia-
betes, glucose-induced suppression of glucose production
(measured with [6-3H]glucose) and total glucose output
(measured with [2-3H]glucose) are not. Furthermore, the
defect in glucose-induced stimulation of glucose uptake
occurs at both low and high insulin concentrations. However,
the severity of the defect is dependent on the prevailing glu-
cose concentration, only becoming evident at glucose con-
centrations above 130 mg/dl, implying saturation of a glucose-
responsive step.
RESEARCH DESIGN AND METHODS
S u b j e c t s . After approval from the Mayo Institutional Review Board, 10 healthy
nondiabetic subjects and 9 subjects with type 2 diabetes gave written consent to
participate in the study. All diabetic subjects were taking sulfonylureas. These
agents were discontinued 3 weeks before study. All subjects were in good health,
had normal blood pressure, and were at stable weight. None regularly engaged
in vigorous exercise or regularly took medications other than sulfonylureas.
Except for one subject, who was adopted, a family history was obtained in all study
subjects. None of the nondiabetic subjects had a family history of diabetes in their
first-degree relatives. The characteristics of the subjects are shown in Table 1. Age,
sex, total body weight, BMI, lean body mass, total body fat, and percent visceral
fat did not differ between groups. The fasting glucose concentration and the
mean GHb concentrations (GlycAffin; Isolab, Akron, OH) (normal range 4–7%)
were higher in the diabetic than in the nondiabetic subjects.
Experimental design. Subjects were admitted to the Mayo Clinic General Clin-
ical Research Center at 1700 on the evening before each study. A standard 10
kcal/kg meal (50% carbohydrate, 15% protein, 35% fat) was eaten between 1730 and
1800. An 18-gauge catheter was inserted into a forearm vein and used for all infu-
sions. The diabetic subjects were infused with insulin (100 U regular human
insulin in 1 L of 0.9% saline containing 0.4 ml 25% human albumin) during the night,
while nondiabetic subjects were infused with saline. The insulin infusion was
adjusted in the diabetic subjects so as to maintain the glucose concentration at ~5
mmol/l throughout the night (26). A cannula was inserted retrogradely into a dor-
sal hand vein at 0600. The hand was then placed in a heated Plexiglas box and main-
tained at a temperature of ~55°C to allow sampling of arterialized venous blood.
An intravenous infusion containing somatostatin (94 ng · kg– 1 · min– 1), glucagon
(1.0 ng · kg– 1 · min– 1), and growth hormone (4.7 ng · kg– 1 · min– 1) was begun in all
subjects at 0600 (–240 min) the following morning. An intravenous infusion of
insulin was also started in nondiabetic subjects at a rate of 0.24 mU · kg– 1 · min– 1,
whereas the variable insulin infusion was continued in the diabetic subjects.
Plasma glucose concentrations were measured at 15-min intervals using a glucose
oxidase method (Beckman Instruments, Brea, CA), and the insulin infusion rate was
adjusted in both groups to maintain glucose at ~5 mmol/l. The last adjustment in
this “basal” insulin infusion was made at least 30 min before starting the study. The
basal insulin infusion (referred to as the low-dose insulin infusion) was terminated
at 180 min and replaced by a 0.78 mU · kg– 1 · min– 1 insulin infusion (referred to as
the high-dose insulin infusion), which was continued until 360 min.
A primed continuous (110 µCi prime, 1.10 µCi/min continuous) infusion of
N a H1 4C O3 was started at 0600, and primed continuous infusions of [2-
3H ] g l u c o s e
and [6-3H]glucose (both 17 µCi prime, 0.17 µCi/min continuous) were started at 0700.
All subjects were studied on three occasions, with the order of study being random.
Beginning at time zero, sufficient glucose (as dextrose) was infused to maintain
the glucose concentration at  ~95 mg/dl (5 mmol/l), ~130 mg/dl (7.3 mmol/l), or ~165
mg/dl (9.3 mmol/l). All infused glucose contained both [2-3H]glucose and [6-3H ] g l u-
cose in an effort to minimize the change in plasma glucose specific activity dur-
ing the study (27). In addition, the rates of the continuous infusions of [2-3H ] g l u-
cose and [6-3H]glucose were maintained at 100% from 0 to 180 min on the 95
mg/dl study day, decreased by 50% on the 130 mg/dl study day, and decreased by
75% on the 165 mg/dl study day. At 180 min, the tracer infusion rates were further
decreased from the 0- to 180-min tracer infusion rates according to the anticipated
decrease in endogenous glucose production during the insulin infusion (23). In the
nondiabetic subjects, the rates were decreased by a further 16% from 180 to 195
min, 29% from 195 to 210 min, 40% from 210 to 225 min, 47% from 225 to 240 min,
57% from 240 to 270 min, 65% from 270 to 300 min, 70% from 300 to 330 min, and
75% from 330 to 360 min. In the diabetic subjects, the rates were decreased by a
further 8% from 180 to 195 min, 15% from 195 to 210 min, 22% from 210 to 225 min,
27% from 225 to 240 min, 37% from 240 to 270 min, 44% from 270 to 300 min, 50%
from 300 to 330 min, and 53% from 330 to 360 min. Arterialized venous blood was
sampled at regular intervals for measurement of glucose and hormone concen-
trations as well as glucose specific activity. Breath was also collected to permit
measurement of 1 4C O2 s p e c i fic activity as previously described (28).
Analytical techniques. Arterialized plasma samples were placed on ice, cen-
trifuged at 4°C, separated, and stored at –20°C until assay. Plasma insulin, C-pep-
tide, and glucagon concentrations were measured by radioimmunoassay using
reagents purchased from Linco Research (St. Louis, MO). Plasma growth hormone
concentration was measured using reagents provided by ICN Biomedicals (Costa
Mesa, CA). Plasma [2-3H]glucose and [6-3H]glucose specific activities were deter-
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TABLE 1
Subject characteristics
C h a r a c t e r i s t i c s D i a b e t i c N o n d i a b e t i c
Age (years) 56 ± 2.9 53 ± 2.4
Sex (M/F) 5 / 4 5 / 5
Total body weight (kg) 78 ± 5.5 82 ± 3.0
BMI (kg/m2) 26 ± 1.6 29 ± 1.4
Lean body mass (kg) 51 ± 3.7 49 ± 3.7
Total body fat (kg) 22 ± 2.9 26 ± 3.4
Visceral fat (%) 36 ± 3.6 35 ± 4.2
GHb (%) 10.2 ± 0.8 5.4 ± 0.2
Fasting glucose (mmol/l) 10.1 ± 0.7 4.9 ± 0.1
Data are means ± SE.
mined by selective enzymatic detritiation as previously described (29). Body
composition and lean body mass were measured by dual-energy X-ray absorp-
tiometry (DPX scanner; Lunar, Madison, WI). Percentage of intra-abdominal adi-
posity was determined using a single-slice computerized tomograph scan at the
level of L2 /L3 (30). Glucose concentrations were measured using a Ye l l o w
Springs glucose analyzer (Yellow Springs Instruments, Yellow Springs, OH).
Plasma free fatty acids (FFAs) were measured enzymatically using a Wako NEFA
C kit (Wako Chemicals, Richmond, VA ) .
C a l c u l a t i o n s . Glucose specific activities were smoothed using the method of
Bradley et al. (31). Glucose appearance and disappearance were calculated using
S t e e l e ’s non–steady-state equations (32). The volume of distribution of glucose was
assumed to equal 200 ml/kg, and the pool correction factor was assumed to be 0.65
(33,34). Endogenous glucose production and total glucose output were determined
by subtracting the glucose infusion rate from the tracer-determined rate of glu-
cose appearance. [6-3H]glucose was used to trace the rate of endogenous glucose
production, and [2-3H]glucose was used to trace total glucose output (35–37).
Hepatic glucose cycling was calculated by subtracting results obtained with [6-
3H]glucose from those obtained with [2-3H]glucose (35–37). All rates of infusion
and turnover are expressed per kilogram of lean body mass. The percent glucose
derived from 1 4C O2 was calculated by dividing the plasma [
1 4C]glucose specific
activity by breath 1 4C O2 s p e c i fic activity (28).
Statistical analysis. Data in the figures and text are expressed as means ± SE.
Values observed from –30 to 0 min on the 3 study days were meaned in each indi-
vidual in order to test for baseline differences. Analysis of variance (ANOVA) for
repeated measures was used to determine whether results differed on the 3 study
days (i.e., 95, 130, and 165 mg/dl). Paired Student’s t test was used to test for
within-group differences. Nonpaired Student’s t test and, when appropriate, Mann-
Whitney rank-sum tests were used to test for between-group differences. One-sided
S t u d e n t ’s t test was used to test the hypotheses that an increase in insulin or glu-
cose concentration suppresses glucose production and stimulates glucose disap-
pearance and that these effects are impaired in people with diabetes. All other tests
were two-sided. A P value <0.05 was considered statistically signific a n t .
R E S U LT S
Glucose, insulin, C-peptide, glucagon, and growth hor-
mone concentrations. Basal (–30 to 0 min) glucose con-
centrations were stable and equal in the diabetic and nondia-
betic subjects on the 3 study days (Fig. 1). Glucose concen-
trations during the euglycemic and hyperglycemic portions of
the studies also did not differ in the diabetic and nondiabetic
subjects, averaging, respectively, 4.88 ± 0.18 vs. 5.15 ± 0.25, 7.3
± 0.17 vs. 7.53 ± 0.16, and 9.23 ± 0.32 vs. 9.36 ± 0.17 mmol/l dur-
ing the final 30 min (150–180 min) of the low-dose insulin
infusions and 5.22 ± 0.13 vs. 5.07 ± 0.11, 7.23 ± 0.18 vs. 7.44 ±
0.10, and 9.46 ± 0.30 vs. 9.45 ± 0.26 mmol/l during the final 30
min (330–360 min) of the high-dose insulin infusions.
The diabetic subjects were infused with insulin during the
night so that glucose concentrations would be equivalent in
both groups at the start of each study. This resulted in
s l i g h t l y, but not signific a n t l y, higher (P = 0.23) basal (–30 to
0 min) insulin concentrations in the diabetic than in the non-
diabetic subjects (103 ± 22 vs. 75 ± 10 pmol/l). Because these
“basal” insulin concentrations were maintained until 180 min,
insulin concentrations during the low-dose insulin infusions
remained slightly higher (108 ± 23 vs. 76 ± 9 pmol/l; P = 0.19)
in the diabetic than in the nondiabetic subjects (Fig. 2).
Insulin concentrations during the high-dose insulin infusions
also did not differ between the two groups (196 ± 17 vs. 201
± 20 µU/ml).
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FIG. 1. Glucose concentrations observed in the diabetic and nondia-
betic subjects when glucose was either clamped at ~95 mg/dl through-
out the experiment or acutely increased at time zero to ~130 or ~165
mg/dl. The insulin infusion was maintained at a constant “basal” rate
(referred to as the low-dose insulin infusion) from 0 to 180 min at
which time it was increased to a rate of 0.79 mU · kg– 1 · min– 1 ( r e f e r r e d
to as the high-dose insulin infusion).
FIG. 2. Insulin concentrations observed in the diabetic and nondia-
betic subjects when glucose concentrations were either clamped at
~95 mg/dl throughout the experiment or acutely increased at time zero
to either ~130 or ~165 mg/dl. The insulin infusion rate was maintained
at a constant “basal” rate (referred to as the low-dose insulin infusion)
from 0 to 180 min at which time it was increased to a rate of 0.79 mU ·
kg–1 · min–1 (referred to as the high-dose insulin infusion ) .
C-peptide concentrations were suppressed both before
and during the clamps in both groups (Table 2). However, C-
peptide increased slightly, but signific a n t l y, in the nondia-
betic subjects when glucose was raised from 95 to 130 to 165
mg/dl during both the low-dose (P = 0.04) and high-dose (P
= 0.004) insulin infusions. C-peptide concentrations did not
change in the diabetic subjects. Glucagon and growth hor-
mone (data not shown) concentrations remained constant
and equal in both groups on all 3 study days (Table 2).
Plasma glucose specific activity. Plasma [6-3H ] g l u c o s e
(Fig. 3A) and [2-3H]glucose (Fig. 3B) specific activities were
maintained within 15% of basal values in both groups on all
3 study days.
Endogenous glucose production and total glucose 
ou t p u t . Both [6-3H]glucose and [2-3H]glucose were infused,
since the two tracers assess different aspects of glucose
metabolism. [2-3H]glucose, but not [6-3H]glucose, is exten-
sively detritiated during equilibration with the hepatic (and per-
haps renal) glucose-6-phosphate (G-6-P) pool (35). Therefore
[ 2 -3H]glucose taken up by the liver then subsequently released
back into the systemic circulation will no longer be labeled.
Thus, [6-3H]glucose measures endogenous glucose produc-
tion, whereas [2-3H]glucose measures total glucose output.
Basal (–30 to 0 min) rates of endogenous glucose produc-
tion (Fig. 4A) and total glucose output (Fig. 4B) were com-
parable on the 3 study days in both groups. Rates in the dia-
betic subjects did not differ from those in the nondiabetic sub-
jects. Endogenous glucose production and total glucose
output fell slowly during the low-dose insulin infusion (i.e.,
from 0 to 180 min) in both the diabetic and nondiabetic sub-
jects when plasma glucose concentration was maintained at
95 mg/dl, presumably because of an increasing duration of
fast. In contrast, an increase in glucose concentration at time
zero to either 130 or 165 mg/dl resulted in a prompt decrease
in endogenous glucose production and total glucose output
in both groups. Dose-response curves (Fig. 5A and B) were
constructed by plotting the mean rates of glucose production
and output during the final 30 min (150–180 min) of the low-
dose insulin infusion versus the prevailing plasma glucose
concentration. These curves demonstrated that an increase
in glucose from 95 to 130 to 165 mg/dl caused a parallel
decrease (P = 0.001–0.002 by ANOVA) in both endogenous glu-
cose production and total glucose output in both the dia-
betic and nondiabetic subjects.
Endogenous glucose production and total glucose output
were further suppressed when the insulin infusion rate was
increased at 180 min (Fig. 4). Endogenous glucose production
was greater (P = 0.05) in the diabetic than nondiabetic
groups during the 95 mg/dl study, but it did not differ during
the 130 and 165 mg/dl studies. Because of already low rates,
glucose production in the nondiabetic subjects did not sup-
press further as glucose was raised from 95 to 130 to 165 mg/dl
(Fig. 5C). In contrast, glucose production in the diabetic sub-
jects further decreased (P = 0.02 by ANOVA) when glucose
was increased. Total glucose output was comparably sup-
pressed in both groups during the high-dose insulin infusion,
and it did not differ in the diabetic and nondiabetic subjects
on any of the 3 study days (Fig. 5D). Hepatic glucose cycling
(calculated by subtracting endogenous glucose production
from total glucose output) also did not differ between the
groups on any of the 3 study days (Table 3).
Incorporation of 1 4C O2 into glucose. Incorporation of
1 4C O2 into glucose was greater (P = 0.02) in the diabetic than
in the nondiabetic subjects in the basal state (Fig. 6). Incor-
poration of 1 4C O2 into glucose increased from 0 to 180 min in
both groups on the 95 mg/dl study day, presumably refle c t i n g
an increase in the contribution of gluconeogenesis to systemic
glucose release due to the increased duration of fast. In con-
trast, the incorporation of 1 4C O2 into glucose remained con-
stant from 0 to 180 min on the 130 mg/dl study day and
decreased on the 165 mg/dl study day. Dose-response curves
were constructed by plotting results observed during the
final 30 min of the low-dose insulin infusion versus the pre-
vailing glucose concentration (Fig. 7A). These curves indi-
cated that the percentage of glucose derived from 1 4C O2 p r o-
gressively decreased when glucose concentration was
increased 95 to 130 to 165 mg/dl in both the diabetic (P = 0.001
by ANOVA) and nondiabetic (P = 0.003 by ANOVA) subjects.
Incorporation of 1 4C O2 into glucose was slightly higher (P =
0.06) in the diabetic than in the nondiabetic subjects during
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TABLE 2
Plasma glucagon and C-peptide concentrations when glucose concentration was maintained at 95, 135, and 165 mg/dl
0 min 30 min 60 min 90 min 120 min 150 min 180 min 210 min 240 min 270 min 300 min 330 min 360 min
Glucagon (pg/ml)
95 mg/dl
D i a b e t i c 78.7 ± 4.5 78.6 ± 4.6 74.8 ± 4.6 76.0 ± 5.4 75.6 ± 4.6 77.0 ± 4.8 77.0 ± 5.3 82.2 ± 5.6 78.0 ± 4.9 78.7 ± 4.6 79.0 ± 4.7 77.4 ± 4.8 78.7 ± 7.2
N o n d i a b e t i c 78.8 ± 5.8 77.5 ± 6.5 74.6 ± 5.9 77.4 ± 5.9 74.5 ± 5.8 76.3 ± 6.8 77.3 ± 6.9 73.0 ± 5.9 74.5 ± 5.8 73.1 ± 7.4 77.8 ± 6.6 75.0 ± 5.8 78.3 ± 7.0
130 mg/dl
D i a b e t i c 80.4 ± 5.6 79.6 ± 6.0 83.0 ± 4.4 84.0 ± 6.1 84.1 ± 6.5 79.9 ± 5.6 82.0 ± 3.7 80.2 ± 5.7 79.4 ± 5.6 78.7 ± 4.8 79.8 ± 4.4 83.2 ± 4.4 75.8 ± 5.3
N o n d i a b e t i c 81.9 ± 10.0 82.8 ± 8.9 81.1 ± 8.9 81.2 ± 8.3 83.5 ± 7.3 80.5 ± 7.0 84.3 ± 8.3 83.9 ± 9.6 83.7 ± 9.0 79.4 ± 9.6 83.6 ± 9.7 80.1 ± 9.3 81.0 ± 10.7
165 mg/dl
D i a b e t i c 79.8 ± 8.5 76.0 ± 8.0 75.7 ± 7.7 74.9 ± 7.3 77.2 ± 5.8 78.2 ± 7.9 80.3 ± 7.0 76.2 ± 8.4 77.0 ± 8.2 75.3 ± 7.3 76.6 ± 8.1 80.1 ± 7.9 77.6 ± 8.8
N o n d i a b e t i c 80.3 ± 5.7 77.1 ± 5.8 75.0 ± 2.9 76.1 ± 5.1 76.9 ± 4.5 77.9 ± 6.2 75.0 ± 5.9 71.7 ± 5.8 76.9 ± 5.9 74.6 ± 5.4 74.2 ± 5.6 73.6 ± 6.0 71.7 ± 5.0
C-peptide (nmol/l)
95 mg/dl
D i a b e t i c 0.03 ± 0.00 0.03 ± 0.00 0.03 ± 0.00 0.03 ± 0.01 0.03 ± 0.00 0.03 ± 0.00 0.03 ± 0.00 0.03 ± 0.01 0.03 ± 0.00 0.03 ± 0.00 0.03 ± 0.00 0.03 ± 0.004 0.03 ± 0.004
N o n d i a b e t i c 0.06 ± 0.00 0.06 ± 0.01 0.06 ± 0.00 0.06 ± 0.01 0.05 ± 0.01 0.05 ± 0.01 0.04 ± 0.01 0.04 ± 0.01 0.04 ± 0.00 0.04 ± 0.01 0.04 ± 0.01 0.04 ± 0.004 0.04 ± 0.004
130 mg/dl
D i a b e t i c 0.03 ± 0.00 0.03 ± 0.00 0.03 ± 0.00 0.02 ± 0.00 0.02 ± 0.00 0.03 ± 0.01 0.02 ± 0.00 0.02 ± 0.00 0.02 ± 0.00 0.03 ± 0.00 0.02 ± 0.00 0.02 ± 0.003 0.03 ± 0.004
N o n d i a b e t i c 0.05 ± 0.01 0.06 ± 0.01 0.05 ± 0.01 0.05 ± 0.01 0.05 ± 0.01 0.07 ± 0.02 0.06 ± 0.01 0.05 ± 0.01 0.05 ± 0.01 0.05 ± 0.01 0.05 ± 0.01 0.05 ± 0.006 0.04 ± 0.004
165 mg/dl
D i a b e t i c 0.03 ± 0.01 0.04 ± 0.01 0.03 ± 0.01 0.04 ± 0.00 0.03 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.03 ± 0.006 0.03 ± 0.006
N o n d i a b e t i c 0.04 ± 0.00 0.05 ± 0.00 0.12 ± 0.11 0.08 ± 0.01 0.09 ± 0.01 0.12 ± 0.01 0.10 ± 0.01 0.09 ± 0.01 0.10 ± 0.01 0.11 ± 0.02 0.11 ± 0.02 0.15 ± 0.008 0.12 ± 0.009
Data are means ± SE.
the low-dose insulin infusion at a glucose concentration of 95
mg/dl, with the difference becoming less evident when glu-
cose was increased to 130 or 165 mg/dl.
The increase in the insulin infusion rate at 180 min resulted
in a decrease in incorporation of 1 4C O2 into glucose in both
groups. However, the degree of suppression was less in the
diabetic than in the nondiabetic subjects, resulting in the
percentage of glucose derived from 1 4C O2 being higher (P =
0.01–0.001) in the former than the latter on all 3 study days.
Hyperglycemia further decreased (P = 0.001 by ANOVA )
incorporation of 1 4C O2 into glucose in the diabetic subjects but
did not alter the already suppressed rates in the nondiabetic
subjects (Fig. 7B) .
Glucose disappearance. Basal (–30 to 0 min) rates of glu-
cose disappearance were comparable on the 3 study days in
both groups and did not differ in the diabetic and nondiabetic
subjects (Fig. 8). Glucose disappearance changed minimally
from 0 to 180 min on the 95 mg/dl study day. Disappearance
transiently increased in both groups when glucose was
acutely raised to 130 or 165 mg/dl. Glucose disappearance
during the final 30 min of the low-dose insulin infusion was
lower (P = 0.005–0.02) in the diabetic than in the nondiabetic
subjects on all 3 study days (Figs. 8 and 9). An increase in glu-
cose concentration from 95 to 130 mg/dl was accompanied
by a comparable increase in glucose disappearance in both
the diabetic (14.2 ± 0.8 to 18.2 ± 1.1 µmol · kg– 1 · min– 1) and
nondiabetic (19.9 ± 1.8 to 23.6 ± 1.8 µmol · kg– 1 · min– 1) sub-
jects. In contrast, whereas an increase in glucose to 165
mg/dl resulted in a further increase (P = 0.02) in glucose dis-
appearance in the nondiabetic subjects (to 25.4 ± 1.6 µmol ·
k g– 1 · min– 1), it did not alter disappearance in the diabetic sub-
jects (to 18.7 ± 2.4 µmol · kg– 1 · min– 1; P = 0.41).
Glucose disappearance during the high-dose insulin infu-
sion showed a similar pattern. Glucose disappearance was
lower (P = 0.03–0.001) in the diabetic than in the nondiabetic
subjects during the final 30 min of the high-dose insulin infu-
sion on all 3 days (Figs. 8 and 9). Once again, an increase in
glucose from 95 to 130 mg/dl was accompanied by a com-
parable increase in glucose disappearance in both the dia-
betic (21.0 ± 3.2 to 33.9 µmol · kg– 1 · min– 1) and nondiabetic
(36.4 ± 3.1 to 47.6 ± 4.5 µmol · kg– 1 · min– 1) subjects. Whereas
an increase in glucose to 165 mg/dl resulted in a further
increase (P = 0.02) in glucose disappearance in the nondia-
betic subjects (to 61.1 ± 7.0 µmol · kg– 1 · min– 1), it did not alter
glucose disappearance in the diabetic subjects (to 32.5 ±
8.0 µmol · kg– 1 · min– 1; P = 0.37).
Urinary glucose excretion. Urinary glucose excretion on
the 95, 135, and 165 mg/dl study days averaged, respectively,
0.05 ± 0.02, 0.10 ± 0.04, and 0.26 ± 0.12 µmol · kg– 1 · min–1 i n
the diabetic subjects and 0.01 ± 0.00, 0.01 ± 0.00, and 0.02 ±
0.00 µmol · kg– 1 · min– 1 in the nondiabetic subjects. The rate
of urinary glucose excretion was greater (P = 0.03) in the dia-
betic than in the nondiabetic subjects on both the 135 and 165
mg/dl study days.
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FIG. 3. Plasma [6-3H]glucose (A) and [2-3H]glucose (B) specific activities observed in the diabetic and nondiabetic subjects when glucose con-
centration was either clamped at ~95 mg/dl throughout the experiment or acutely increased at time zero to either ~130 or ~165 mg/dl. The insulin
infusion rate was maintained at a constant “basal” rate (referred to as the low-dose insulin infusion) from 0 to 180 min at which time it was
increased to a rate of 0.79 mU · kg– 1 · min– 1 (referred to as the high-dose insulin infusion).
Plasma FFA concentrations. Basal (–30 to 0 min) FFA
concentrations were higher (P = 0.01) in the diabetic than in
the nondiabetic subjects (Fig. 10). Hyperglycemia sup-
pressed FFA concentrations in both the diabetic (P = 0.02 by
A N O VA) and nondiabetic (P = 0.06 by ANOVA) subjects dur-
ing the low-dose insulin infusion. The high insulin infusion
suppressed FFAs in both groups; however, concentrations
remained higher in the diabetic than in the nondiabetic sub-
jects (P = 0.07, 0.03, and 0.01, respectively, on the 95, 130, and
165 mg/dl study days). Hyperglycemia did not further suppress
F FA concentration during the high-dose insulin infusion.
D I S C U S S I O N
People with poorly controlled type 2 diabetes have abnor-
malities in both glucose production and glucose utilization
(1–3). Glucose production is inappropriately high and glu-
cose uptake is inappropriately low for the prevailing glucose
and insulin concentrations (1–3). The present studies indi-
cate that insulin-induced suppression but not glucose-induced
suppression of glucose release is impaired in type 2 diabetes.
Hyperglycemia comparably inhibited glucose release in both
groups regardless of whether it was assessed with a tracer ([6-
3H]glucose) that measures net glucose production or a tracer
( [ 2 -3H]glucose) that measures total glucose output. Further-
more, hyperglycemia also equally suppressed the rate of
incorporation of 1 4C O2 into glucose in both groups, suggesting
comparable regulation of gluconeogenesis by glucose. In con-
trast, glucose-induced stimulation of its own uptake is abnor-
mal in type 2 diabetes. This defect is demonstrable in the
presence of both basal and suprabasal insulin concentrations
and is evident at glucose concentrations above but not below
130 mg/dl, implying saturation of a glucose-responsive step.
E ffects of glucose on glucose release. Both we and others
have previously demonstrated that glucose can inhibit its own
production (7,22–24,38). However, to the best of our knowl-
edge, the present studies are the first to simultaneously defin e
the glucose dose-response curves for suppression of glucose
production and total glucose output in humans. This is likely
because methods for accurately measuring glucose production
and output at varying glucose levels have only recently
become available. Particular care was taken to ensure that glu-
cose specific activity was kept constant throughout the study
so as to minimize errors in the measurement of glucose
appearance and disappearance (27,34). Only purified tracers
were used (39). The euglycemic and hyperglycemic clamps
were performed on separate days to preclude falsely ascrib-
ing time-dependent changes in turnover to the effects of
sequential increases in glucose concentration.
Both Del Prato et al. (24) and Ader et al. (5) have also
recently examined the ability of glucose to suppress endoge-
nous glucose production in the presence of basal insulin con-
centrations. In contrast to the present experiments, the
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FIG. 4. Endogenous glucose production (A) and total glucose output (B) observed in the diabetic and nondiabetic subjects when glucose con-
centration was either clamped at ~95 mg/dl throughout the experiment or acutely increased at time zero to either ~130 or ~165 mg/dl. The insulin
infusion rate was maintained at a constant “basal” rate (referred to as the low-dose insulin infusion) from 0 to 180 min at which time it was
increased to a rate of 0.79 mU · kg– 1 · min– 1 (referred to as the high-dose insulin infusion).
experiments of Del Prato et al. suggested that suppression of
endogenous glucose production was nonlinear; minimal sup-
pression was observed when glucose concentration was
raised from ~90 to ~145 mg/dl, with marked suppression
occurring thereafter. Although those experiments were care-
fully conducted by an experienced group of investigators, the
apparent nonlinearity was probably due to the fact that glu-
cose concentrations were sequentially increased and glu-
cose specific activity was not clamped. The progressive fall
in glucose specific activity with each increase in glucose con-
centration likely resulted in a progressive underestimation of
glucose appearance that, in turn, resulted in what appeared
to be enhanced suppression of glucose production at higher
glucose concentrations (27,34). In contrast, Ader et al. used
the constant specific activity method to measure glucose
production in dogs (5). In agreement with the present stud-
ies, those experiments indicated linear suppression of
endogenous glucose production at glucose concentrations
within the range commonly observed in nondiabetic humans
after food ingestion (i.e., 95–165 mg/dl). However, it is impor-
tant to emphasize that this conclusion pertains to the presence
of basal insulin concentrations. Previous studies have estab-
lished that permissive amounts of insulin are required for glu-
cose to suppress its own release (38,40). Conversely, an
increase in glucose has little or no further effect when glucose
production is already markedly suppressed by high insulin
concentrations (22).
One of the primary purposes of the present experiments
was to determine whether glucose-induced suppression of
glucose production is altered by type 2 diabetes. Endoge-
nous glucose production is commonly increased in hyper-
glycemic individuals with poorly controlled diabetes
(12,41–44). This could be due in whole or in part to a failure
of glucose to suppress its own release. Alternatively, it could
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FIG. 5. Dose-response curves for suppression of glucose production (A and C) and total glucose output (B and D). Mean rates of glucose pro-
duction and glucose output observed during the final 30 min of the low-dose (A and B) and high-dose (C and D) insulin infusions are plotted
versus the mean plasma glucose concentration observed over the same interval.
TABLE 3
Hepatic glucose cycling (µmol · kg– 1 · min– 1)
Glucose concentration
Low-dose insulin (mg/dl) High-dose insulin (mg/dl)
9 5 1 3 0 1 6 5 9 5 1 3 0 1 6 5
Diabetic subjects 2.61 ± 1.03 3.84 ± 1.70 3.76 ± 1.25 0.70 ± 1.45 3.22 ± 1.43 7.08 ± 2.39
Nondiabetic subjects 3.94 ± 0.97 6.14 ± 1.22 5.27 ± 1.72 3.31 ± 1.15 3.88 ± 2.76 1.90 ± 2.65
Data are means ± SE.
A B
DC
be due to relative insulin deficiency and/or insulin r e s i s t a n ce .
We have attempted to distinguish between these two possi-
bilities by infusing the diabetic subjects with insulin during
the night so that their glucose concentrations would be the
same as the nondiabetic subjects at the beginning of each
experiment. On the morning of study, insulin secretion was
inhibited in both groups by infusing somatostatin, and
“basal” insulin concentrations (defined as that required to
maintain euglycemia) were determined for each individual.
Glucose concentrations were clamped at predetermined lev-
els so that the effects of glucose could be directly compared.
When glucose was clamped at 95 mg/dl during the high-dose
insulin infusion (i.e., a traditional euglycemic-hyperinsu-
linemic clamp), endogenous glucose production was higher
and glucose disappearance was lower in the diabetic than in
the nondiabetic subjects, indicating that the diabetic subjects
were resistant to insulin. Nevertheless, each increment in glu-
cose concentration resulted in a comparable decrement in
glucose production in both groups (Fig. 5). As in the nondi-
abetic subjects, suppression in the presence of basal insulin
concentrations over the glucose concentrations tested
appeared to be linear. Hyperglycemia also decreased glucose
production in the diabetic subjects in the presence of higher
insulin concentrations; however, the further suppress i o n
was limited, since inhibition was already nearly complete.
Glucose-induced suppression of total glucose output was
also equivalent in the diabetic and nondiabetic subjects. To t a l
glucose output was measured with [2-3H]glucose, whereas
endogenous glucose production was measured with [6-
3H]glucose. [2-3H]glucose, but not [6-3H]glucose, is exten-
sively detritiated when glucose is taken up by the liver, phos-
phorlyated via glucokinase, dephosphorylated via glucose-6-
phosphatase, then released back into the systemic
circulation (35,45). Thus, turnover measured with [2-3H ] g l u-
cose is higher than that measured with [6-3H]glucose, since
the former measures the total glucose output whereas the lat-
ter measures net glucose production (29,36,37). The difference
in rates measured with the two tracers is frequently referred
to as “futile” (since energy is consumed) or hepatic glucose
cycling. Experiments in both rats and humans have demon-
strated that uncontrolled diabetes is associated with
increased futile cycling, due, at least in part, to an increase in
glucose-6-phosphatase activity (7,36). The present experi-
ments demonstrate that hepatic glucose cycling no longer dif-
fers in diabetic and nondiabetic subjects when euglycemia is
maintained overnight. This is consistent with the report of
Massillon et al. (46) that normalization of glucose in rats
with either insulin or the glycosuric agent phlorizin causes
rapid normalization of glucose-6-phosphatase gene expres-
sion. Perhaps more importantly, an increase in glucose in
the presence of basal insulin concentrations comparably
decreased total glucose output in both groups, indicating
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FIG. 6. Percentage of glucose derived from 1 4C O2 observed in the dia-
betic and nondiabetic subjects when glucose concentration was either
clamped at ~95 mg/dl throughout the entire experiment or acutely
increased at time zero to either ~130 or ~165 mg/dl. The insulin infu-
sion rate was maintained at a constant “basal” rate (referred to as the
low-dose insulin infusion) from 0 to 180 min at which time it was
increased to a rate of 0.79 mU · kg– 1 · min– 1 (referred to as the high-
dose insulin infusion).
FIG. 7. Dose-response curves for suppression of the incorporation of
1 4C O2 into glucose. The mean percent of glucose derived from 
1 4C O2
observed during the final 30 min of the low-dose (A) and high-dose (B)
insulin infusions is plotted versus the mean glucose concentration
observed over the same interval.
that hyperglycemic-induced suppression of endogenous glu-
cose production in the diabetic subjects is not offset by an
increase in hepatic glucose cycling. Note, however, that the
methods used in the present experiments measure only glu-
cose that is released into the systemic circulation (45).
Cycling that occurs entirely within either the splanchnic or
renal beds is not assessed.
Both in vitro and in vivo studies indicate that poorly con-
trolled diabetes is associated with increased rates of gluco-
neogenesis (7,44,47,48). Unfortunately, quantitative meas-
urement of gluconeogenesis in humans is difficult (49,50). As
discussed elsewhere, we and others have used the rate of
incorporation of 1 4C O2 into glucose as a qualitative index of
gluconeogenesis (28,50,51). Consistent with previous exper-
iments, insulin-induced suppression of 1 4C O2 i n c o r p o r a t i o n
into glucose was impaired in the diabetic subjects (52). Rates
were higher in the diabetic than in the nondiabetic subjects
during the high insulin infusion at all three glucose concen-
trations (Fig. 7). On the other hand, glucose-induced sup-
pression appeared to be intact; this was particularly evident
during the basal insulin infusion when suppression was par-
allel in the diabetic and nondiabetic subjects. Hyperglycemia
also suppressed 1 4C O2 incorporation into glucose during the
high insulin infusion in the diabetic subjects but not the non-
diabetic subjects, where suppression was already essentially
complete. The overall pattern of suppression of 1 4C O2 i n c o r-
poration in the two groups closely resembled that of endoge-
nous glucose production. Because endogenous glucose pro-
duction equals the sum of glycogenolysis and gluconeogen-
esis, this suggests that hyperglycemia similarly suppressed
both processes. Alternatively, hyperglycemia may have
merely redirected the G-6-P derived from either glycogenol-
ysis or gluconeogenesis back into glycogen or down the gly-
colytic pathway (7). Because we have measured only the
portion of the newly synthesized [1 4C]glucose that was even-
tually released into the systemic circulation, and since we
have not used a method that quantitatively measures gluco-
neogenesis, future studies will be required to distinguish
between these possibilities.
E ffects of glucose on glucose uptake. The present stud-
ies once again confirm that insulin-induced stimulation of
glucose uptake is impaired in type 2 diabetes (9–12). They also
demonstrate that whereas glucose-induced stimulation of
glucose uptake is normal at glucose concentrations below 130
mg/dl, it is impaired at glucose concentrations above 130
mg/dl. This pattern was observed at both basal insulin con-
centrations and insulin concentrations two- to threefold
above basal. Numerous investigators (including ourselves)
have examined glucose effectiveness in type 2 diabetes, and
the results have not always been consistent (14,15,23,24).
Many have used the so-called minimal model for this purpose
(14–18). This model measures the net effects of glucose on
both production and utilization. Most (14–16) but not all (17)
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FIG. 8. Rates of glucose disappearance observed in the diabetic and
nondiabetic subjects when glucose concentration was either clamped
at ~95 mg/dl throughout the entire experiment or acutely increased at
time zero to ~130 or ~165 mg/dl. The insulin infusion rate was main-
tained at a constant “basal” rate (referred to as the low-dose insulin
infusion) from 0 to 180 min at which time it was increased to a rate
of 0.79 mU · kg– 1 · min–1 (referred to as the high-dose insulin infusion).
FIG. 9. Dose-response curves for stimulation of glucose disappearance.
The mean rates of glucose disappearance observed during the final 30
min of the low-dose (A) and high-dose (B) insulin infusions are plot-
ted versus the mean glucose concentration observed over the same
i n t e r v a l .
of these studies have found that SG is decreased in individu-
als with type 2 diabetes. When interpreted in light of the
demonstration in the present study that glucose-induced sup-
pression of glucose release is normal in type 2, these studies
are consistent with a decrease in glucose-induced stimulation
of glucose disposal. This conclusion is supported by several
additional studies. Both we (23), using a prandial glucose
infusion, and Avogaro et al. (25), using the so-called hot min-
imal model, have previously shown that glucose-induced
stimulation of glucose uptake is impaired in the presence of
basal insulin concentrations in type 2 diabetes. In addition, Del
Prato et al. (24), using the glucose clamp technique, and Man-
darino et al. (53), using the leg balance method, have also
reached the same conclusion.
In contrast, Baron et al. (54) and Capaldo et al. (55) have
reported that glucose-mediated uptake is either normal or
increased in type 2 diabetes. However, both of these investi-
gators examined uptake in the presence of zero insulin con-
centrations (frequently referred to as non–insulin-mediated
glucose uptake). While of considerable theoretical interest,
the physiological significance of these findings is uncertain
because insulin concentrations are rarely, if ever, zero in peo-
ple with type 2 diabetes. Of perhaps more concern are our
own previous results. We failed to detect an abnormality in
glucose-induced stimulation of uptake in type 2 diabetes in
another series of experiments in which glucose effective-
ness was assessed in the presence of an insulin concentration
normally observed in nondiabetic subjects after food inges-
tion (22). We were puzzled by those results when we subse-
quently found, as noted above, that glucose stimulation of dis-
posal was impaired in the presence of basal insulin concen-
trations (23). We speculated that the discrepant results were
due to the differences in insulin concentrations between the
two experiments. The present experiments indicate that this
was not the case but rather suggest that the differences were
due to differences in glucose concentrations. In our earlier
experiments, we calculated glucose effectiveness by sub-
tracting glucose disposal rates observed when glucose con-
centrations were varied so as to mimic postprandial levels
from those observed when glucose was clamped at eugly-
cemic levels (22). Because we were mimicking a nondiabetic
p r o file, glucose concentrations were only briefly above 130
mg/dl. In contrast, since glucose concentrations were per-
mitted to rise unencumbered in our experiment in which
glucose effectiveness was assessed in the presence of basal
insulin levels, concentrations in excess of 220 mg/dl were
reached in the diabetic subjects (23). The demonstration in
the present experiments that the ability of glucose to stimu-
late its own disposal is impaired in diabetic subjects at glu-
cose concentrations above, but not below, 130 mg/dl explains
why an abnormality in glucose effectiveness was detected in
the latter but not the former experiments. It also explains why
experiments using the minimal model have generally found
SG to be decreased, since the diabetic subjects were invariably
hyperglycemic at the time of study and since glucose con-
centrations rose to extremely high levels after intravenous glu-
cose injection (14–16,18,25).
The observation that the glucose dose-response curve for
stimulation of glucose uptake flattens at a lower concentra-
tion in diabetic than in nondiabetic subjects implies satura-
tion of a rate-limiting step that is regulated by glucose.
Although this early flattening was not commented on in the
experiments of Del Prato et al. (24), this likely reflects the fact
that the first step in glucose concentration (to ~155 mg/dl) was
above the apparent threshold (~130 mg/dl) noted in the pres-
ent studies. In addition, the increment in uptake was calcu-
lated by subtracting baseline rates of disappearance deter-
mined before initiation of the somatostatin and basal hormone
infusions from rates of disappearance determined several
hours later. Finally, progressive increases in urinary glucose
excretion presumably contributed to the apparent incre-
ments in glucose uptake that were observed in the diabetic
subjects when glucose was sequentially increased to ~210 and
~300 mg/dl, thereby obscuring the effects of glucose on tis-
sue glucose utilization. While these factors confound inter-
pretation of the shape of the glucose dose-response curves for
disappearance, they do not detract from the fact that the dif-
ferences between the diabetic and nondiabetic subjects in the
experiments of Del Prato et al. (24) were substantial, strongly
implying that the ability of glucose to stimulate glucose
uptake in the presence of basal insulin concentrations was
impaired in type 2 diabetes.
Glucose transport/phosphorylation is a likely candidate
for the decrease in uptake, since previous studies have
shown that it is rate limiting at low levels of flux (6,56,57). In
this regard, it is important to note that the insulin concen-
trations present during the so-called high-dose insulin study
fall on the lower portion of the insulin dose-response curve
for stimulation of glucose uptake (8,9,58). Early saturation of
transport could result from a decrease in the number or func-
tion of membrane-bound glucose transporters. Alternatively,
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FIG. 10. Mean FFA concentrations during the final 30 min of the low-
dose (A) and high-dose (B) insulin infusions when glucose concen-
trations were either maintained at ~95 mg/dl throughout the experi-
ment or acutely increased at time zero to either ~135 or ~165 mg/dl.
a more distal step such as phosphorylation or glycogen syn-
thesis could become rate limiting at higher glucose concen-
trations. Transport, phosphorylation, and glycogen synthesis
are all modulated by both glucose and insulin concentra-
tions (6,59,60). Insulin-induced regulation of all three
processes has been reported to be abnormal in type 2 diabetes
(56,57,61–64). A defect in glucose-induced regulation of any
or all of these processes could explain the present fin d i n g s .
Such a defect could be due to an intrinsic abnormality in a
common intracellular signaling pathway or could be sec-
ondary to the metabolic milieu associated with type 2 diabetes
(e.g., elevated FFAs, such as those observed in the present
experiments). Whatever the mechanism, it is likely not a sim-
ple matter of a decrease in the absolute number/activity of
transporters; an increase in glucose concentration in the dia-
betic subjects from 95 to 130 mg/dl further stimulated uptake
during the high-dose insulin infusion but did not do so when
glucose was increased from 130 to 165 mg/dl during the low-
dose insulin infusion despite the fact that the absolute rate of
disposal was greater in the former than in the latter instance.
A l t e r n a t i v e l y, the defect may reside in the liver rather than in
muscle. If so, then this would imply abnormal regulation of
hepatic enzyme activity, since transport does not limit glucose
uptake in this tissue. Additional studies will be required to dis-
tinguish between these possibilities.
L i m i t a t i o n s . As with all experiments, the present studies
have certain limitations. We have only examined glucose
effectiveness between glucose concentrations of 95 and 165
mg/dl. We chose this range for both theoretical and practical
reasons. First, it encompasses the concentrations normally
observed in nondiabetic humans before and after food inges-
tion (1–3). Second, it is below the renal threshold of most indi-
viduals, thereby minimizing the uncertainty introduced by the
need to correct glucose disappearance for urinary glucose
losses. Third, in our experience, glucose concentrations
above 165 mg/dl frequently cause a breakthrough in insulin
secretion despite the presence of somatostatin, and glucose
concentrations below 95 mg/dl are frequently accompanied
by secretion of counterregulatory hormones. Both occur-
rences confound assessment of insulin action and glucose
effectiveness. Therefore, the present experiments do not per-
mit comment on glucose effectiveness above 165 mg/dl or
below 95 mg/dl.
S i m i l a r l y, we only examined two insulin concentrations.
We chose to study “basal” insulin concentration because this
potentially provides insight into the effects of glucose after an
overnight fast and because this is the insulin concentration at
which the widely used minimal model estimates glucose
effectiveness (13). We chose the high-dose insulin infusion
because it results in insulin concentrations that fall on the
lower portion of the insulin dose-response curve for the stim-
ulation of glucose uptake (8,9,58) and that approximate
insulin concentrations frequently observed after eating a
mixed meal (1–3). As previously discussed in detail (22,23), we
chose to individually determine appropriate “basal” insulin
concentration (defined as that required to maintain eugly-
cemia) for each subject on each study day. Because of the pres-
ence of insulin resistance, this resulted in slightly higher
insulin concentrations in diabetic than in nondiabetic sub-
jects. Alternatively, we could have used the same basal insulin
infusion rate in both groups; however, this approach would
likely have resulted in glucose concentrations that were ris-
ing in the diabetic subjects at the start of the experiments. In
this instance, we potentially would incorrectly conclude that
the rising glucose concentration and its associated inappro-
priately high rates of glucose production and inappropriately
low rates of glucose uptake were due to defects in glucose
effectiveness when in fact they were due to relative insulin defi-
c i e n c y. We adopted the alternative approach (i.e., we used the
same insulin infusion rate in both groups) during the higher
dose insulin study because we were primarily interested in glu-
cose disposal and therefore wanted to ensure that peripheral
insulin concentrations were the same in both groups. While
both approaches have their limitations, the fact that they both
yielded concordant results during the low and high insulin infu-
sions is obviously reassuring.
Insulin was infused during the night in the diabetic subjects
so that glucose concentrations would be the same in both
groups at the beginning of the experiments. We have previ-
ously demonstrated that while insulin resistance persists
after overnight insulin infusion (52), insulin administration
and/or the associated improvement in glycemic control
improves hepatic but not extrahepatic insulin action (65). In
contrast, we have found in preliminary experiments that
overnight insulin infusion does not alter glucose effectiveness
(R.B., unpublished observations). Thus, while the present
experimental design may have underestimated the severity of
hepatic insulin resistance, it is unlikely to have had an impact
on the assessment of glucose effectiveness. Because the
studies were conducted in humans, insulin was infused into
the peripheral rather than into the portal venous system.
While it is possible that different conclusions would have
been reached if insulin had been infused into the portal cir-
culation, we doubt it, since recent studies have shown simi-
lar hepatic responses regardless of the route of infusion
(66–68). C-peptide concentrations increased from 0.05 to
0.09 nmol/l in the nondiabetic subjects when glucose was
raised to 165 mg/dl. Assuming that this was accompanied by
an increase in portal insulin concentrations, this would have
been a conservative error, since, if anything, it would have
overestimated glucose-induced suppression of glucose pro-
duction in the nondiabetic subjects. We measured [6-3H ] g l u-
cose and [2-3H]glucose specific activities in the peripheral cir-
culation rather than in the hepatic bed. Because we do not
know specific activity within the hepatic bed, we also do not
know total rates of hepatic glucose cycling (45). Similarly, we
do not know whether the relative contribution of the kidney
and liver to systemic glucose production differed in the dia-
betic and nondiabetic subjects. We merely know that net
response of the tissues to an increase in glucose was equal in
both groups.
We used the rate of incorporation of 1 4C O2 into glucose as
an index of gluconeogenesis. The advantages and disadvan-
tages of this technique have been discussed in detail else-
where (28,50,51). Because labeling occurs as pyruvate is con-
verted to oxaloacetate by pyruvate carboxylase, this method
suffers from the same limitations as does the use of alanine
or lactate for the same purpose (49–51). However, dilution
within the oxaloacetate pool appears to remain relatively
constant under a wide range of conditions (50,69,70). There-
fore, it is likely that the similar pattern of change in the incor-
poration of 1 4C O2 into glucose in the diabetic and nondiabetic
subjects reflects a similar degree of suppression of the con-
tribution of gluconeogenesis to systematically released glu-
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cose. We did not correct glucose disappearance for urinary
glucose loss; although we measured total urinary glucose
excretion during the clamps, we do not know whether the rate
of excretion was the same throughout the 6 h of study. Nev-
ertheless, this represents a conservative error, since urinary
glucose excretion was trivial in the nondiabetic subjects at all
glucose concentrations but averaged up to 1–2 µmol · kg– 1 ·
m i n– 1 in some of the diabetic subjects during the 165 mg/dl
clamp. Therefore, subtraction of urinary losses from tracer-
determined rates of glucose disappearance would further
flatten the dose-response curve for glucose uptake in the
diabetic subjects. The BMI of the diabetic subjects averaged
26 kg/m2 with a range of 18–33 kg/m2. Additional studies will
be required to determine whether the conclusions of the
present study apply to more obese type 2 diabetic subjects.
Of note, the BMI of the diabetic subjects was slightly but not
s i g n i ficantly greater than that of the nondiabetic subjects.
H o w e v e r, percent visceral fat was virtually identical in both
groups (Table 1), implying that the impaired hepatic
response to insulin but normal responses to glucose in the dia-
betic relative to the nondiabetic subjects cannot be attributed
to differences in visceral adiposity.
S u m m a r y. In conclusion, the present experiments once
again show that people with type 2 diabetes have both
hepatic and extrahepatic insulin resistance. However, their
response to glucose may or may not be abnormal depending
on the tissue involved. In the presence of basal insulin con-
centrations, an increase in glucose over the range of 95–165
mg/dl causes a progressive and comparable decrease in
endogenous glucose production and total glucose output in
both diabetic and nondiabetic subjects, implying a normal
hepatic (and perhaps renal) response to glucose. In contrast,
the ability of glucose to stimulate its own uptake is impaired.
This defect is evident at glucose concentrations above 130
mg/dl and is observed in the presence of low and high insulin
concentrations. Thus, these studies provide experimental
support for the assumption that glucose-induced suppres-
sion of its own release is linear and does not differ in diabetic
and nondiabetic humans. They also imply that therapies that
enhance glucose-induced, as well as insulin-induced, stimu-
lation of glucose uptake are likely to improve glycemic tol-
erance in people with type 2 diabetes.
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